• A K Wutoh, J Hidalgo, J Bareta, W Rhee, R Beardsley, and S Steidl.
• Department of Clinical and Administrative Pharmacy, Howard University College of Pharmacy, Washington, DC 20059, USA.
• J Natl Med Assoc. 1998 Apr 1; 90 (4): 214220214-20.

AbstractThis historical cohort study assessed the impact of race on critical factors in the diagnosis and drug treatment of cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome (AIDS) patients over a 7-year period. The study subjects included 194 adult patients with a history of AIDS who were treated for CMV retinitis between September 1987 and September 1994. Abstracted inpatient hospital medical records and a statewide automated AIDS database were the primary sources of data. Patients were assessed for severity of CMV retinitis at diagnosis, time from initial CMV retinitis diagnosis to first treatment, survival from diagnosis of AIDS, and initiation of drug treatment for CMV retinitis. Results indicated a significant difference in the severity of CMV retinitis at diagnosis by race. Patients diagnosed with early disease were more likely to be white, whereas patients diagnosed with severe disease were more likely to be black. There was no difference in the type of CMV retinitis treatment or patient survival time after diagnosis, nor time to treatment once diagnosed by race. These results suggest that differences in survival may not be the result of discrimination against black patients and may be due more likely to practices associated with accessing medical treatment.

13 keywords...

hide…